10th Symposium “Advances in Cancer Immunology and Immunotherapy”

46
Speakers
3
Days
156
Registrations
10
Sponsors
Scientific Program
Τα πιστοποιητικά είναι διαθέσιμα!
Δεν υπάρχουν διαθέσιμα δεδομένα. Επικοινωνήστε μαζί μας μέσω email ζητώντας την πιστοποίησή σας ή καλέστε μας για να σας βοηθήσουμε.

Chairs: C.N. Baxevanis (GR), J. Wischhusen (DE)
08.40-09.00 Conversion of monocytes into myeloid-derived
suppressor cells in cancer V. Umansky (DE)
09.00-09.20 Ying and yang of extracellular matrix proteins in tumor development and immune surveillance: novel therapeutic targets? B. Seliger (DE)
09.20-09.40 Discussion

Chairs: J. Wischhusen (DE), T. Frisan (SE)
10.00-10.20 Pre-existing immunity in non-small cell lung cancer A. Xagara (GR)
10.20-10.40 Immunosuppressive environment in pancreatic cancer V. Bronte (IT)
10.40-11.00 Modulating the tumor-microenvironment in pancreatic cancer D. Öhlund (SE)
11.00-11.20 Discussion

Chairs: S. Karagiannis (UK), A. Eliopoulos (GR)
11.20-11.40 Dysfunctional T lymphocytes identified by spatial analysis in the microenvironment of Pancreatic Ductal Adenocarcinoma T. Frisan (SE)
11.40-12.00 Microbiota-gut-brain axis in glioblastoma development O. Martin (FR)
12.00-12.20 Discussion

Chairs: P. Verginis (GR), M. Goulielmaki (GR)

1. HIGH-DIMENSIONAL CYTOF ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN MGUS, SMOLDERING MM, AND MM N. Paschalidis

2. EXPLORING TCR REPERTOIRE AND IMMUNE-RELATED GENES AS POTENTIAL BIOMARKERS IN HEAD AND NECK CANCER P. Batsaki

3. IDENTIFICATION OF A NOVEL IMMUNE-GENE SIGNATURE WITH PROGNOSTICVALUE IN PATIENTS WITH HEAD AND NECK CANCER P. Batsaki

4. TRANSFORMING GROWTH FACTOR BETA IMPACTS NATURAL KILLER CELL PHENOTYPE AND FUNCTIONALITY G. Isvoranu

5. A RARE CASE OF SIGNET RING CELL ADENOCARCINOMA OF THE BLADDER IN A YOUNG WOMAN C. Belantis

6. CHLOROQUINE -MEDIATED INDUCTION OF HLA-CLASS-I IN LUNG CANCER CELL LINES: IMPLICATIONS IN ANTI-PD-L1 IMMUNOTHERAPY E. Xanthopoulou

7. PRECLINICAL EVALUATION OF THE ANTI-CANCER ACTIVITY OF OLE-16, A NEW SYNTHETIC ANALOG OF OLEUROPEIN C. Knai

8. INVESTIGATION OF CELLULAR SENESCENCE IN THE BONE MARROW DURING MULTIPLE MYELOMA PROGRESSION N. Poulis

Chairs: C.N. Baxevanis (GR), V. Umansky (DE)
15.00-15.20 CAR-T cell and beyond for the treatment of malignant disorders and other conditions. A. Madrigal (UK)
15.20-15.40 Targeting onco-fetal immune tolerance mechanisms for
cancer immunotherapy J. Wischhusen (DE)
15.40-16.00 Immunotherapeutic strategies for solid tumours N. Mensali (NO)
16.00-16.20 Discussion

Chairs: M. Koukourakis (GR), C.N. Baxevanis (GR)
Radiotherapy induced cGAS re-localization and immune signature
in HNSCC as a predictor of treatment efficacy G. Adema (NL)

Chairs: E. Saloustros (GR), V. Georgoulias (GR)
Novel therapeutic approaches in gynecological cancer O. Fiste (GR)

Chairs: C.Ν. Βaxevanis (GR), S. Karagiannis (UK)
18.30-19.00 Novel approaches for glioblastoma vaccination C. Gouttefangeas (DE)
19.00-19.30 The cystine/glutamate antiporter in breast cancer:
an xCTing target F. Cavallo (IT)

Chairs: S. Karagiannis (UK), N. Mensali (NO)
08.40-09.00 Novel insight in tumor microenvironment in liver cancer A A. Chatzigeorgiou (GR)
09.00-09.20 Charting the Cancer Battlefield: Unraveling Tumor Microenvironments and Immunotherapy Dynamics N. de Miranda (NL)
09.20-09.40 Novel immune-based biomarkers in common solid tumors I. Pateras (GR)
09.40-10.00 Discussion

Chairs: T. Frisan (SE), N. de Miranda (NL)
10.30-10.50 Blood immunomap to predict immunotherapy responses P. Verginis (GR)
10.50-11.10 ERAP1 as a regulator of the immunopeptidome, proteome and ER homeostasis of cancer cells E. Stratikos (GR)
11.10-11.30 Antibody-drug conjugates (ADCs) for cancer therapy designed through the study of the tumour microenvironment S. Karagiannis (UK)
11.30-11.50 Discussion

Chairs: F. Cavallo (IT), I. Pateras (GR)

9. DEVELOPMENT OF AN INNOVATIVE HYDROGEL PRINTING HEAD FOR PRINTING OSTEOCHONDRAL STRUCTURES V. Fanidis

10. EO2401, A NOVEL IMMUNOTHERAPY, PLUS NIVOLUMAB INDUCES A STRONG IMMUNE RESPONSE IN RECURRENT GLIOBLASTOMA A. Maia Santos Leite

11. ALTERATIONS IN MINIMAL RESIDUAL DISEASE STATUS MODIFIES THE INITIAL PROGNOSTICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS I.V. Kostopoulos

12. COMPREHENSIVE ANALYSIS OF DIFFERENT CIRCULATED T-CELL SUBTYPES IN PDAC PATIENTS K. Vasilieva

13. CELLULAR IMMUNIOTHERAPY:A NEW CHALLENGE IN AN ALREADY PROMISING FIELD K. Folinas

14. MECHANISMS OF THE PD-1/PD-L1 PATHWAY IN IMMUNE EVASION OF HNSCC E. Litsou

Chairs: F. Koinis (GR), G. Pawelec (DE)
14.00-14.20 The biomarker utility of T-cells in NSCLC M. Goulielmaki (GR)
14.20-14.40 Dissecting the tumor microenvironment in early breast cancer: clinical implications and novel insights A. Matikas (SE)
14.40-15.00 Targeting co stimulatory molecules for cancer immunotherapy: good or bad idea? G. Marodon (FR)
15.00-15.20 Epigenetic regulation in cancer A. Klinakis (GR)
15.20-15.40 Discussion

Chairs: H. Gogas (GR), D. Ziogas (GR)
15.40-16.00 Cytomegalovirus and immunosenescence:
impact on melanoma immunotherapy G. Pawelec (DE)
16.00-16.20 Advances in the management of early stage melanoma - the role of Immunotherapy A. Laskarakis (GR)
16.20-16.50 10yrs of IO evolution in mMelanoma G. Lazarides (GR)
sponsord by BMS
16.50-17.00 Discussion

Chairs: K. Tsapakidis (GR), V. Georgoulias (GR)
17.15-17.45 New horizons in 1L metastastatic NSCLC with dual IO
G. Mountzios (GR)
Sponsored Lecture BMS
17.45-18.15 Early - Stage NSCLC and Immunotherapy: Unraveling Mechanistic Pathways for Improved Outcomes A. Cortellini (IT)
Sponsored Lecture ASTRAZENECA
18.15-18.45 Advances in the treatment algorithm of resectable NSCLC: improving overall survival with immunotherapy T. Füreder (AT)
Sponsored Lecture MSD
18.45-19.15 State of the art of immunotherapy in the first line setting
in NSCLC D. Papadatos-Pastos (UK)
19.15-19.30 Discussion

Chair: A. Kotsakis (GR)
Novel Data in SCLC K. Leventakos (US)

Chairs: A. Kotsakis (GR), V. Papadopoulos (GR)
08.40-09.00 Immunotherapy in urothelial carcinomas P. Tsantoulis (CH)
09.00-09.20 Combining radiotherapy and immunotherapy M. Koukourakis (GR)
09.20-09.30 Discussion

Chairs: A. Kotsakis (GR), V. Papadopoulos (GR)
The value of the Claudin 18.2 biomarker for the management of Gastric and Gastro-esophageal Junction Carcinomas M. Avgoustidou
Sponsored Lecture ASTELLAS

Chairs: S. Karagiannis (UK), A. Klinakis (GR)
Bio-informatic analysis in cancer immunology and immunotherapy S. Tsoka (UK)

Abstracts Awards - Organizing Committee

Adema G.
Professor, Chair in Molecular Immunology, Radiotherapy & OncoImmunology laboratory, Department of Radiation Oncology RadboudUMC, Nijmegen, The Netherlands
Avgoustidou M.
MD, Medical Oncologist, Palliative Medicine
Baxevanis C.
Scientific Director, Cancer Immunology and Immunotherapy Center, Agios Savvas Hospital, Athens, Greece
Bronte V.
Professor, Allergy and Clinical Immunology, Scientific Director of the Veneto Institute of Oncology IOV - IRCCS (Comprehensive Cancer Center), Padova, Italy
Cavallo F.
Professor, Immunology, Department of Molecular Biotechnology and Health Sciences Molecular, Biotechnology Center “Guido Tarone”, University of Torino, Torino, Italy
Chatzigeorgiou A.
BSc, MD, PhD, Associate Professor of Experimental and Clinical Physiology, Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Cortellini A.
Consultant Medical Oncologist - Asst Professorm Campus Bio-Medico, Rome, Italy
de Miranda N.
Principal Investigator, Immunogenomics group, Associate Professor, Department of Pathology, Leiden University, Medical Center (LUMC), Leiden, The Netherlands
Eliopoulos A.
Professor of Biology & Genetics, Head of the Department of Biology, School of Medicine, National & Kapodistrian University of Athens (NKUA), Athens, Greece
Fiste O.
Fellow in Medical Oncology, Medical Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece
Frisan T.
Professor, Department Molecular Biology, Umeå Centre for Microbial Research (UCMR), Umeå University, Sweden
Füreder T.
Assoc. Professor, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Georgoulias V.
Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Heraklion, Crete, Greece
Gogas H.
Professor of Medical Oncology, 1st Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Goulielmaki M.
PhD, Post-doctoral Researcher, Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Greece
Gouttefandeas C.
Professor, Group leader at the Institute for Immunology, Tübingen, Germany
Karagiannis S.
Professor of Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences , King’s College London, Guy’s Hospital, London, UK
Klinakis A.
PhD, Director of Research - Professor level, Biomedical Research Foundation of the Academy of Athens, Greece
Koinis F.
MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Kotsakis A.
MD, PhD, Associate Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larisa, Thessaly, Greece
Koukourakis M.
Radiation Oncologist, Professor, Medical School, Democritus University of Thrace - Head Dept of Radiotherapy - Oncology, Radiobiology and Radiopathology Unit, Universiy Hospital of Alexandroupolis, Greece
Laskarakis A.
MD, MSc, Medical Oncologist, Director, Oncology Department, Medical Center of Athens, Athens
Lazarides G.
MD, PhD, Medical Oncologist, Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece
Leventakos K.
MD, PhD, Assistant Professor, Chest oncology and clinical studies phase 1, Mayo Clinic, Rochester, USA
Madrigal A.
MD, PhD, FRCP, FRCPath, DSc, HonDSci, FMedSci, Professor of Haematology, UCL Cancer Institute, Honorary Consultant, Royal Free NHS Trust, UCL Country Ambassador for México
Marodon G.
CRHC | Inserm | Centre for Immunology and Microbial Infections -CIMI-PARIS, Sorbonne University, Paris, France
Martin O.
PhD, HDR, Associate Professor in clinical microbiology, University of Bordeaux, CNRS U5095, France
Matikas A.
Associate Professor of Oncology, Karolinska Institutet, Stockholm, Sweden
Mensali N.
PhD, Msc, Researcher, Postdoc Fellow, Dept of Cellular Therapy, Oslo University Hospital, Oslo, Norway
Mountzios I.
Consultant-Medical Oncologist, 2 nd Oncology Department and Clinical T rials Unit, Henry Dunant Hospital, Oncolife Institute Founder
Öhlund D.
MD, PhD, Assistant Professor, Umeå University, Dept. of Radiation sciences and Wallenberg Centre of Molecular Medicine (WCMM), Sweden
Papadatos – Pastos D.
MRCP (UK) PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, London, UK
Papadopoulos V.
MD, Oncologist, Consultant, Department of Oncology, University Hospital, Larisa, Greece
Pateras I.
Bsc, MD, PhD, Pathologist, Assistant Professor, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Pawelec G.
Professor of Experimental Immunology, Department of Immunology, University of Tübingen, Tübingen, Germany, Health Sciences North Research Institute, Sudbury, Ontario, Canada
Saloustros E.
Assistant Professor of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa
Seliger B.
Professor of Immunology, Institute of Medical Immunology, Martin - Luther - University Halle - Wittenberg, Halle, Germany
Stratikos E.
Associate Professor, Biochemistry Department of Chemistry, National and Kapodistrian University of Athens, Greece
Tsantoulis P.
MD, PhD, Medical Oncologist, Department of Oncology, Univ ersity Hospital of Geneva, Center for Translational Oncohematology, University of Geneva (HUG), Swiss Cancer Center Leman, Geneva, Switzerland
Tsapakidis K.
Medical Oncologist, University Hospital of Larissa, Greece
Tsoka S.
Reader in Bioinformatics, Department of Informatics | Faculty of Natural, Mathematical and Engineering Sciences | King’s College London, London, UK
Umansky V.
PhD, Professor, Clinical Cooperation Unit Dermato-Oncology (A370), German Cancer Research Center (DKFZ), Foundation under Public Law, Heidelberg, Germany
Verginis P.
Associate Professor Immunology, Biochemistry, School of Medicine, University of Crete, Heraklion, Greece
Wischhusen J.
PhD, Professor of Experimental Tumor Immunology, University of Würzburg School of Medicine, Department of Gynecology and Obstetrics, Germany
Xagara Α.
Molecular Biologist, PhD, Laboratory of Oncology, University of Thessaly, Larissa
Ziogas D.
MD, PhD, Academic Scholar in Medical Oncology 1st Department of Internal Medicine, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens

Technical Support is available:

- everyday 09:00-17:00

- at the day of the event 09:00-21:00

For Technical Support please contact us:

Phone: +30 210 72 40 039

Email: support@livetime.gr

 

Event Details
Add to Calendar
Sponsors
Share This Event